Dolvidin 50 mg, 600 mg, 300 mg Tablet
PDF Leaflet Revision Date: 19 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents.
Dosage (summary)
One tablet once daily for adults and adolescents over 40 kg.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy (peri-conception and first trimester) and breastfeeding.
Key Drug Interactions
- Dofetilide
- Metformin
- Polyvalent cation-containing antacids
Contraindications
- Hypersensitivity to abacavir, dolutegravir, or lamivudine
- Moderate and severe hepatic impairment
- Creatinine clearance < 50 mL/min
Common side effects
- Hypersensitivity reactions
- Nausea
- Diarrhoea
- Fatigue
- Rash
Counselling Points
- Inform about hypersensitivity risks and symptoms.
- Never restart DOLVIDIN after hypersensitivity.
- Regular monitoring for opportunistic infections is necessary.
Serious warnings
- Risk of life-threatening hypersensitivity reactions
- Lactic acidosis
- Immune reconstitution inflammatory syndrome
Important Disclaimer
The Dolvidin 50 mg, 600 mg, 300 mg Tablet professional information leaflet below is the property of Novagen Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
